---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-002260"
form_type: "8-K"
ticker: null
cik: "0001318641"
company_name: "Statera Biopharma, Inc."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:33:45.930907+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Statera declares Series B Preferred dividend with super-voting rights for share increase and reverse split

## Summary
- Declared dividend of 1/1,000th share of Series B Preferred per common share; record date Feb 1, 2023.
- Series B carries 1,000 votes per share, voting only on Authorized Share Increase (150M to 250M) and Reverse Split (1-for-10 to 1-for-300).
- Unvoted Series B shares automatically redeemed before meeting at $0.005 per whole share (with rounding exclusions).
- Bylaws amended to reduce stockholder quorum from majority to 33.34% of votes entitled to be cast.

## SEC filing metadata
- accession: 0001437749-23-002260
- form_type: 8-K
- cik: 0001318641
- company_name: Statera Biopharma, Inc.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/0001437749-23-002260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/cbli20230131_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-002260
- JSON: https://secwatch.observer/filing/0001437749-23-002260.json
- Plain text: https://secwatch.observer/filing/0001437749-23-002260.txt

## Key facts
- Governance Changes
  Statera Biopharma, Inc.: Established Series B Preferred Stock and filed Certificate of Designation setting forth preferences, rights, and limitations (effective 2023-01-26).
  - Change: charter amendment
  - Effective: 2023-01-26
  source text: On January 26, 2023, the board of directors (the "Board") of Statera Biopharma, Inc. (the "Company") declared a dividend of one one-thousandth of a share of Series B Preferred Stock, par value $0.005 per share ("Series B Preferred Stock"), for each outstanding share of the Company's common stock, par value $0.005 per share ("Common Stock") to stockholders of record at 5:00 p.m. Eastern Time on February 1, 2023 (the "Record Date"). Series B Certificate of Designation The preferences, rights, limitations and other matters relating to the Series B Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the "Certificate of Designation").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/0001437749-23-002260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.